Rigel Pharmaceuticals | RIGL - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
Agenus USD 22.44M 1.14M 2025-12
Amgen USD 9.14B 432M 2026-03
Anika Therapeutics USD 29.33M 661K 2025-12
Arrowhead Research USD 15.68M 203.19M 2026-03
AstraZeneca USD 17.88B 1.17B 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Celldex Therapeutics USD 230K 1.78M 2026-03
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
Eli Lilly USD 21.18B 1.02B 2026-03
Halozyme Therapeutics USD 457.99M 16.72M 2026-03
Heron Therapeutics USD 89.59M 8.54M 2025-12
Intrexon USD 1.02M 559K 2024-06
Ionis Pharmaceuticals USD 74M 8M 2026-03
Karyopharm Therapeutics USD 26.18M 5.6M 2025-12
Ligand Pharmaceuticals USD 54.8M 6.25M 2026-03
MacroGenics USD 13.37M 55.86M 2025-12
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
Pfizer USD 16.17B 332M 2026-03
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Rigel Pharmaceuticals USD 28.9M 1.39M 2024-06
Sangamo BioSciences USD 581K 110K 2024-06
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Veracyte USD 50.11M 5.45M 2026-03